Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation

Abstract

Hypercholesterolemia is characterized by elevated low-density lipoprotein (LDL)-cholesterol levels and an increased risk of cardiovascular disease. The adipokine chemerin is an additional risk factor. Here we investigated whether cholesterol-lowering with statins or proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) affects chemerin. Both statins and PCKS9i lowered plasma LDL-cholesterol, triglycerides and total cholesterol in hypercholesterolemic patients, and increased high-density lipoprotein (HDL)-cholesterol. Yet, only statins additionally reduced chemerin and high-sensitivity C-reactive protein (hsCRP). Applying PCSK9i on top of statins did not further reduce chemerin. Around 20% of chemerin occurred in the HDL₂/HDL₃ fractions, while >75% was free. Statins lowered both HDL-bound and free chemerin. Pull-down assays revealed that chemerin binds to the HDL-component Apolipoprotein A-I (ApoA-I). The statins, but not PCSK9i, diminished chemerin secretion from HepG2 cells by upregulating LDL receptor mRNA. Furthermore, chemerin inhibited HDL-mediated cholesterol efflux via its chemerin chemokine-like receptor 1 in differentiated macrophages. In conclusion, statins, but not PCSK9i, lower circulating chemerin by directly affecting its release from hepatocytes. Chemerin binds to ApoA-I and inhibits HDL-mediated cholesterol efflux. Statins prevent this by lowering HDL-bound chemerin. Combined with their anti-inflammatory effect evidenced by hsCRP suppression, this represents a novel cardiovascular protective function of statins that distinguishes them from PCSK9i.

Keywords

chemerin / hypercholesterolemia / lipoprotein subfractions / PCSK9 inhibitors / statin

References

[1] Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020; 383(8): 711-720.

[2] Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. 2018; 138(2): 141-149.

[3] Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021; 8: 687585.

[4] Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018; 14(3): 215-224.

[5] Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308(23): 2497-2506.

[6] Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020; 878: 173114.

[7] Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance? JAMA. 2016; 315(15): 1571-1572.

[8] Tan L, Chen Z, Sun F, et al. Placental trophoblast-specific overexpression of chemerin induces preeclampsia-like symptoms. Clin Sci (Lond). 2022; 136(4): 257-272.

[9] Ferland DJ, Mullick AE, Watts SW. Chemerin as a driver of hypertension: a consideration. Am J Hypertens. 2020; 33(11): 975-986.

[10] Garces MF, Sanchez E, Acosta BJ, et al. Expression and regulation of chemerin during rat pregnancy. Placenta. 2012; 33(5): 373-378.

[11] Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21(11): 660-667.

[12] Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life. 2014; 66(1): 19-26.

[13] Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003; 198(7): 977-985.

[14] Tan L, Ouyang Z, Chen Z, et al. Adipokine chemerin overexpression in trophoblasts leads to dyslipidemia in pregnant mice: implications for preeclampsia. Lipids Health Dis. 2023; 22(1): 12.

[15] Inci S, Aksan G, Dogan P. Chemerin as an independent predictor of cardiovascular event risk. Ther Adv Endocrinol Metab. 2016; 7(2): 57-68.

[16] Sun JX, Zhang C, Cheng ZB, et al. Chemerin in atherosclerosis. Clin Chim Acta. 2021; 520: 8-15. doi:10.1016/j.cca.2021.05.015

[17] Tan L, Lu X, Danser AHJ, Verdonk K. The role of chemerin in metabolic and cardiovascular disease: a literature review of its physiology and pathology from a nutritional perspective. Nutrients. 2023; 15(13): 2878.

[18] Lorincz H, Katko M, Harangi M, et al. Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. Clin Endocrinol (Oxf). 2014; 81(3): 370-377.

[19] Guo Y, Huo J, Wu D, et al. Simvastatin inhibits the adipogenesis of bone marrow-derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling. Int J Mol Med. 2020; 46(2): 751-761.

[20] Kofink D, Eppinga RN, van Gilst WH, et al. Statin effects on metabolic profiles: data from the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). Circ Cardiovasc Genet. 2017; 10(6): e001759.

[21] Varga VE, Lorincz H, Zsiros N, et al. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. Lipids Health Dis. 2016; 15(1): 182.

[22] Ferland DJ, Seitz B, Darios ES, et al. Whole-body but not hepatic knockdown of chemerin by antisense oligonucleotide decreases blood pressure in rats. J Pharmacol Exp Ther. 2018; 365(2): 212-218.

[23] Neves KB, Nguyen Dinh Cat A, Lopes RA, et al. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. Hypertension. 2015; 66(3): 657-666.

[24] Sotiropoulos GP, Dalamaga M, Antonakos G, et al. Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer. Lung Cancer. 2018; 125: 291-299.

[25] Maghsoudi Z, Kelishadi R, Hosseinzadeh-Attar MJ. The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents. Diabetes Metab Syndr. 2016; 10(Suppl 1 2): S43-S46.

[26] Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010; 72(3): 342-348.

[27] Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC. Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation. PLoS One. 2013; 8(2): e57802.

[28] Ha YJ, Kang EJ, Song JS, Park YB, Lee SK, Choi ST. Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity. Joint Bone Spine. 2014; 81(2): 189-190.

[29] Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019; 74(12): 1594-1607.

[30] Gu P, Cheng M, Hui X, Lu B, Jiang W, Shi Z. Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients. J Hypertens. 2015; 33(8): 1624-1632.

[31] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267-1278.

[32] Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010; 95(6): 2892-2896.

[33] Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-alpha. Endocrinology. 2010; 151(6): 2590-2602.

[34] Bauer S, Wanninger J, Schmidhofer S, et al. Sterol regulatory element-binding protein 2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes. Endocrinology. 2011; 152(1): 26-35.

[35] Chen JC, Wu ML, Huang KC, Lin WW. HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc Res. 2008; 80(1): 138-150.

[36] Ohta M, Kawano H, Notsu T, Naba H, Imada K. Eicosapentaenoic acid attenuates statin-induced ER stress and toxicity in myoblast. Biochem Biophys Res Commun. 2012; 424(2): 301-307.

[37] Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8(4): 222-232.

[38] Galema-Boers AMH, Lenzen MJ, Sijbrands EJ, Roeters van Lennep JE. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience. J Clin Lipidol. 2017; 11(3): 674-681.

[39] Galema-Boers AM, Lenzen MJ, Engelkes SR, Sijbrands EJ, Roeters van Lennep JE. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J Clin Lipidol. 2018; 12(2): 409-416.

[40] Schreuder MM, Hamkour S, Siegers KE, et al. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: a sex and gender-specific analysis. Atherosclerosis. 2023; 384: 117117.

[41] Versmissen J, Vongpromek R, Yahya R, et al. Familial hypercholesterolaemia: cholesterol efflux and coronary disease. Eur J Clin Invest. 2016; 46(7): 643-650.

[42] Yahya R, Jainandunsing S, Rashid M, et al. HDL associates with insulin resistance and beta-cell dysfunction in South Asian families at risk of type 2 diabetes. J Diabetes Complications. 2021; 35(10): 107993.

[43] Sun Y, Tan L, Neuman RI, et al. Megalin, proton pump inhibitors and the renin-angiotensin system in healthy and pre-eclamptic placentas. Int J Mol Sci. 2021; 22(14): 7407.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.